Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Release

Printer Friendly Version View printer-friendly version
<< Back
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY

HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, President and Chief Executive Officer, and Jonathan Freve, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the 2019 Cantor Fitzgerald Global Healthcare Conference, which is being held October 2-4, 2019 at the InterContinental New York Barclay Hotel.

 
     
  • Presentation Time: Thursday, October 3rd at 10:05 a.m.
  •  
  • A live audio webcast of the Cantor Fitzgerald Global Healthcare Conference presentation will be available online at http://wsw.com/webcast/cantor10/sbph/
  •  
  • The webcast can also be viewed from the Investors & Media section of the Company's website at https://ir.springbankpharm.com/
  •  
 

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company’s lead product candidate, inarigivir, is being developed for the treatment of chronic hepatitis B virus (HBV). Inarigivir is designed to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense. The company is also developing its lead STING agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers. For more information, please visit www.springbankpharm.com.

Investors:

Spring Bank Pharmaceuticals, Inc.
 
Jonathan Freve
Chief Financial Officer
(508) 473-5993

LifeSci Advisors, LLC
 
Ashley R. Robinson
(617) 535-7742
 Ashley@lifesciadvisors.com

Media:
McNeil, Gray & Rice
 
Kristin Nugent
Senior Account Supervisor
(617) 367-0100

Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank logo.png

Source: Spring Bank Pharmaceuticals, Inc.